bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: J J M A M F J
2018: D N O S A J

 
  Other news for:
Multiple Sclerosis
 Resources from HONselect
FDA OKs New Drug for Multiple Sclerosis

By Robert Preidt

WEDNESDAY, March 27, 2019 (HealthDay News) -- A new pill for relapsing forms of multiple sclerosis (MS) has won approval from the U.S. Food and Drug Administration.

Generally, relapsing MS involves periods of worsening symptoms followed by recovery periods. Over time, some disability follows independent of relapses, and this is called secondary progressive multiple sclerosis, or SPMS.

Approval of the medication Mayzent (siponimod) was based on a clinical trial of more than 1,600 patients with SPMS.

"Multiple sclerosis can have a profound impact on a person's life," said Dr. Billy Dunn, director of the FDA's division of neurology products in the Center for Drug Evaluation and Research.

"We are committed to continuing to work with companies that are developing additional treatment options for patients with multiple sclerosis," Dunn added in an agency news release.

Among patients with active SPMS, those who took the drug had fewer relapses and were less likely to have confirmed progression of MS-related disability after three months than those who received a placebo, the FDA noted.

Among patients with non-active SPMS, the differences between those who took the new Novartis drug and those who received the placebo were not statistically significant.

MS is an autoimmune disease of the central nervous system that disrupts communications between the brain and other parts of the body. Symptoms, which can include blurred vision, muscle weakness and difficulty with balance and coordination, typically appear between ages 20 and 40.

The most common side effects reported by patients taking Mayzent included headache, high blood pressure and liver function problems.

The drug may increase the risk of infections, so patients should have a complete blood count taken before treatment begins, the FDA said. Other potential risks include an eye condition called macular edema; decreases in heart rate; declines in lung function; high blood pressure, and fetal harm in pregnant women.

Health care professionals should monitor patients for a treatable illness called posterior reversible encephalopathy syndrome, according to the FDA. They should also closely watch patients who have had treatment with immunosuppressive/immune-modulating therapies because there may be unintended immunosuppression with Mayzent.

MS is one of the most common causes of neurological disability in young adults and occurs more often in women than in men.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on multiple sclerosis.

SOURCE: U.S. Food and Drug Administration, news release, March 26, 2019

Copyright © 2019 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=744320

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Sclerosis
Multiple Sclerosis
Therapeutics
Blood
Risk
Recurrence
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact